FI92222B - Onkofetala specifika monoklonala antikroppar, förfarande för deras framställning samt användning av dessa - Google Patents

Onkofetala specifika monoklonala antikroppar, förfarande för deras framställning samt användning av dessa Download PDF

Info

Publication number
FI92222B
FI92222B FI862978A FI862978A FI92222B FI 92222 B FI92222 B FI 92222B FI 862978 A FI862978 A FI 862978A FI 862978 A FI862978 A FI 862978A FI 92222 B FI92222 B FI 92222B
Authority
FI
Finland
Prior art keywords
cells
fetal
antigen
antigens
human
Prior art date
Application number
FI862978A
Other languages
English (en)
Finnish (fi)
Other versions
FI92222C (sv
FI862978A0 (sv
FI862978A (sv
Inventor
Jr Joseph H Coggin
Jr William J Payne
Original Assignee
Univ South Alabama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Alabama filed Critical Univ South Alabama
Publication of FI862978A0 publication Critical patent/FI862978A0/sv
Publication of FI862978A publication Critical patent/FI862978A/sv
Application granted granted Critical
Publication of FI92222B publication Critical patent/FI92222B/sv
Publication of FI92222C publication Critical patent/FI92222C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (13)

1. Förfarande för framställning av ett hybridoma, som utsöndrar onkofetalspecifika monoklonala antikroppar, 5 kännetecknat därav, att a) ett djur immuniseras med immuniserande mängder av ett icke-tillväxande, syngeneiskt fostercellspreparat frän mellandräktighetstiden; b) de immuniserade lymfocyterna isoleras frän nämn- 10 da djur; och c) nämnda lymfocyter fusioneras vid lämpliga fu- sionsförhällanden med en immortaliserande cellinje, varvid erhälls hybridomer med identifieringsegenskaper enligt ATCC-depositionerna HB-8663, HB-8664, HB-8665, HB-8666 15 eller HB-8667.
2. Förfarande enligt patentkravet 1, kännetecknat därav, att nämnda hybridoma odlas i närvaro av en musmakrofagcellinje RAW 264.7, ATCC TIB 71.
3. Förfarande enligt patentkravet 1, kanne- 20 tecknat därav, att de monoklonala antikropparna som utsöndras av nämnda cellinjer är specifika för gnagares och människans embryo- och fosterceller och för gnagares och människans tumörceller.
4. Förfarande för framställning en sädan monoklonal 25 antikropp som är specifik för en viss djurtumör, kännetecknat därav, att man odlar en hybridoma med identifieringsegenskaper enligt ATCC-depositionerna HB-8663, HB-8664, HB-8665, HB-8666 eller HB-8667; och tillva-ratar nämnda av denna utsöndrade monoklonala antikropp. 30
5. Förfarande enligt patentkravet 4, känne tecknat därav, att man gallrar ut nämnda monoklonala antikropp frän den grupp antikroppar som inte väsentli-gen har affinitet för normal vävnad hos ett fullvuxet djur. 92222
6. Monoklonal antikropp, kännetecknad därav, att den har följande specifikationsegenskaper: a) immunreaktivitet mot gnagares antigener under mellanskedet i dräktighetsperioden; 5 b) immunreaktivitet mot människans onkofetaltumör- antigener; c) väsentligen ingen immunreaktivitet mot foster-vävnad frän det senare skedet i gnagares dräktighetspe-riod; och 10 d) väsentligen ingen immunreaktivitet mot normal människovävnad; och att den produceras med hjälp av ett hybridoma med identifieringsegenskaper enligt ATCC-depo-sitionerna HB-8663, HB-8664, HB-8665, HB-8666 eller HB- 8667.
7. Monoklonal antikropp enligt patentkravet 6, kännetecknad därav, att den är immunreaktiv mot en onkofetalpolypeptid med en molekylvikt av ca 44 000 - 48 000.
8. Förfarande för detektering av en onkofetalanti- 20 gen i anslutning till en människotumör, känneteck- n a t därav, att man inkuberar ett människoprov, som misstänks innehälla nämnda onkofetalantigen, med en monoklonal antikropp enligt patentkravet 6; och bestämmer om det inträffar nägon väsentlig bindning mellan nämnda anti- 25 gen och nämnda antikropp.
9. Förfarande enligt patentkravet 8, känne- t e c k n a t därav, att det är ett immunometriskt bes-tämningsförfarande ellrt ett kompetetivt immunologiskt bestämningsförfarande. 30
10. Förfarande enligt patentkravet 8, känne- t e c k n a t därav, att bestämningen av den väsentliga bindningen mellan nämnda antigen och nämnda antikropp ut-förs i närvaro av en onkofetalantigen, som stämplats sä att den kan detekteras. 92222
11. Förfarande enligt patentkravet 8, kanne-t e c k n a t därav, att nämnda antingen är en polypeptid, vars molekylvikt är ca 44 000 - 48 000.
12. Förfarande enligt patentkravet 8, k ä n n e -5 tecknat därav, att nämnda antigen är en polypeptid, vars molekylvikt är ca 200 000.
13. Molekylkomplex, som innehäller en vid antigen bunden monoklonal antikropp, kännetecknat därav, att nämnda antigen är en polypeptid, vars molekylvikt 10 är ca 44 000 - 48 000, eller en polypeptid, vars molekylvikt är ca 200 000, och att antikroppen är en antikropp enligt patentkravet 6.
FI862978A 1984-11-21 1986-07-18 Onkofetala specifika monoklonala antikroppar, förfarande för deras framställning samt användning av dessa FI92222C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/673,794 US4686180A (en) 1984-11-21 1984-11-21 Onco-fetal specific monoclonal antibodies, methods of preparation and use
US67379484 1984-11-21
US8502258 1985-11-15
PCT/US1985/002258 WO1986003223A1 (en) 1984-11-21 1985-11-15 Onco-fetal specific monoclonal antibodies, methods of preparation and use

Publications (4)

Publication Number Publication Date
FI862978A0 FI862978A0 (sv) 1986-07-18
FI862978A FI862978A (sv) 1986-07-18
FI92222B true FI92222B (sv) 1994-06-30
FI92222C FI92222C (sv) 1994-10-10

Family

ID=24704144

Family Applications (1)

Application Number Title Priority Date Filing Date
FI862978A FI92222C (sv) 1984-11-21 1986-07-18 Onkofetala specifika monoklonala antikroppar, förfarande för deras framställning samt användning av dessa

Country Status (9)

Country Link
US (1) US4686180A (sv)
EP (1) EP0203967B1 (sv)
JP (1) JPH0683666B2 (sv)
AU (1) AU593229B2 (sv)
CA (1) CA1307218C (sv)
DE (1) DE3583296D1 (sv)
FI (1) FI92222C (sv)
NO (1) NO170691C (sv)
WO (1) WO1986003223A1 (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
FR2571146B1 (fr) * 1984-10-01 1988-02-26 Centre Nat Rech Scient Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
US5320941A (en) * 1986-06-06 1994-06-14 Dallan Young DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
JPH0859089A (ja) * 1994-08-18 1996-03-05 Towa Kogyo Kk ボビン搬送用トレイ
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
CA2250164C (en) 1996-04-05 2011-12-06 South Alabama Medical Science Foundation Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10
DE10346627A1 (de) * 2003-10-08 2005-05-19 Weiss, Stefan, PD Dr. Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
WO2007024825A2 (en) * 2005-08-26 2007-03-01 Genway Biotech, Inc. Immunoaffinity separation and analysis compositions and methods
AU2022213913A1 (en) 2021-01-27 2023-08-17 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440863A (en) * 1978-02-22 1984-04-03 Duke University Breast cyst fluid protein assay
US4272504A (en) * 1978-12-14 1981-06-09 Abbott Laboratories Antibody adsorbed support method for carcinoembryonic antigen assay
US4349528A (en) * 1979-11-21 1982-09-14 The Wistar Institute Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
DE3263249D1 (en) * 1981-08-21 1985-05-30 Hoffmann La Roche Method for the determination of carcinoembryonic antigen (cea) and suitable antibody solution for the determination
JPH0811075B2 (ja) * 1982-06-30 1996-02-07 雄治 松岡 単クローン性抗ｃｅａ抗体

Also Published As

Publication number Publication date
DE3583296D1 (de) 1991-07-25
US4686180A (en) 1987-08-11
NO862920L (no) 1986-07-18
FI92222C (sv) 1994-10-10
AU5196486A (en) 1986-06-18
NO862920D0 (no) 1986-07-18
AU593229B2 (en) 1990-02-08
NO170691C (no) 1992-11-18
EP0203967B1 (en) 1991-06-19
FI862978A0 (sv) 1986-07-18
EP0203967A1 (en) 1986-12-10
CA1307218C (en) 1992-09-08
JPS62501189A (ja) 1987-05-14
JPH0683666B2 (ja) 1994-10-26
NO170691B (no) 1992-08-10
EP0203967A4 (en) 1987-04-10
WO1986003223A1 (en) 1986-06-05
FI862978A (sv) 1986-07-18

Similar Documents

Publication Publication Date Title
Liso et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma
CA1320459C (en) Anti-human pulmonary carcinoma monoclonal antibody
JP3502125B2 (ja) 形質転換細胞の抽出および培養ならびにそれらに対する抗体の製造
JP2735947B2 (ja) Ｂ細胞リンパ腫に対するイディオタイプのワクチン接種
JP3423306B2 (ja) 尿中腫瘍関連抗原、抗原性サブユニットの使用および検出方法
JPS63294779A (ja) ハイブリドマ
IE850192L (en) Tumor specific monoclonal antibodies.
FI92222B (sv) Onkofetala specifika monoklonala antikroppar, förfarande för deras framställning samt användning av dessa
JPH02276573A (ja) 肝炎ｂウイルスに対する単クローン性抗体産生ハイブリツドマ細胞系
JPS62220197A (ja) ヒト非小細胞肺癌および一定の他のヒト癌腫に対する単クロ−ン性抗体および抗原
FI85282B (fi) Foerfarande foer framstaellning av permanenta djur- och humancellinjer.
Payne Jr et al. Mouse monoclonal antibody to embryonic antigen: development, cross-reactivity with rodent and human tumors, and preliminary polypeptide characterization
US5024946A (en) Human monoclonal antibody to antigen of gastric cancer and B-cell line for producing this antibody, method for preparing this B-cell line and antibody, antigen and method of preparation of this antigen
US5106738A (en) Tumor specific monoclonal antibodies
EP0216854A4 (en) MONOCLONAL ANTIBODIES AND TEST PROCEDURE.
Ferrone et al. IMMUNOGENICITY OF HLA ANTIGENS PURIFIED FROM SERUM1
EP0253646B1 (en) Anti-human gastric cancer monoclonal antibody
Cantrell et al. Correlations between humoral immunity and successful chemotherapy-immunotherapy
CA1316848C (en) Monoclonal antibody recognizing un-natural ganglioside gd
JPH05506241A (ja) ３５ｋｄ腫瘍関連タンパク質抗原および免疫複合体
CA1294905C (en) Anti-lafora body monoclonal antibody
JPH0249589A (ja) Ｈｌａクラスｉｄｎａおよびｄｎａプローブ並びに形質転換細胞
Hellström et al. Antigens in human melanomas detected by using monoclonal antibodies as probes
JPS6233199A (ja) モノクロ−ナル抗体
Ran et al. The relationship of membrane antigens on 141 (NZB) and EL4 (C57BL) lymphoma cells as demonstrated by antibodyinduced resistance to complement‐mediated cytotoxicity

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION